

Research Article: New Research | Sensory and Motor Systems

Disruption of hyaluronic acid in skeletal muscle induces decreased voluntary activity via chemosensitive muscle afferent sensitization in male mice

https://doi.org/10.1523/ENEURO.0522-21.2022

Cite as: eNeuro 2022; 10.1523/ENEURO.0522-21.2022

Received: 16 November 2021 Revised: 25 February 2022 Accepted: 9 March 2022

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2022 Queme et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1	Title: Disruption of hyaluronic acid in skeletal muscle induces decreased voluntary activity		
2	via chemosensitive muscle afferent sensitization in male mice.		
3			
4	Abbreviated Title: Muscle HA disruption sensitizes chemoreceptors		
6 7	Luis F Queme ^{1,2,5} , Adam Dourson ¹ , Megan C Hofmann ¹ , Ally Butterfield ¹ , Rudolph D. Paladini ^{3*} , Michael P Jankowski ^{1,2,4,5}		
8			
9	1. Department of Anesthesia, Division of Pain Management, Cincinnati Children's		
10	Hospital Medical Center, Cincinnati, OH 45229		
11	2. Department of Anesthesiology, University of Cincinnati, Cincinnati, OH 45229		
12	3. Halozyme, Inc. San Diego, CA 92121		
13 14	4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229.		
15	5. Pediatric Pain Research Center, Cincinnati Children's Hospital Medical Center,		
16	Cincinnati, OH 45229		
17	*Current Institution: Halo Biosciences, Stanford, CA 94301		
18			
19	Author Contributions: LFQ, AD, AB, and MCH Performed Research. LFQ, RP, and MPJ		
20	Designed Research. LFQ, AD, and MPJ Wrote the paper.		
21	The second secon		
22	Correspondence should be addressed to:		
23			
24	3333 Burnet Avenue, MLC6016		
25			
26	Telephone: (513) 803-7966		
27	E-mail: michael.jankowski@cchmc.org		
28			
29	Number of Figures: 4		
30	Number of Tables: 3		
31	Number of words for Abstract: 250		
32	Number of words for Significance Statement: 120		
33	Number of words for Introduction: 593		
34	Number of words for Discussion: 1673		
35			
36			
37	Conflict of Interest: Yes. This research was performed while under a research contract		
38	with Halozyme Inc., manufacturers of the hyaluronidase product used (PEGPH20).		
39	• • • • • • • • • • • • • • • • • • • •		
40	Funding sources: This work was partially funded by a research contract with Halozyme		
41	Inc. This work was also supported by a grant to MPJ from the NIH (R01NS113965).		
42			
43			

Abstract:

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

PEGPH20, a human recombinant hyaluronidase, has been proposed as a coadjutant to pancreatic cancer chemotherapy. In early trials, patients reported increased widespread muscle pain as the main adverse reaction to PEGPH20. To understand how PEGPH20 caused musculoskeletal pain, we systemically administered PEGPH20 to male mice and measured voluntary wheel activity and pain-related behaviors. These were paired with ex-vivo electrophysiology of primary sensory neurons, whole DRG realtime PCR, and immunohistochemistry of hindpaw muscle. PEGPH20 induced significantly lower wheel running, compared to vehicle treated animals, and decreased mechanical withdrawal thresholds 5 days after PEGPH20 injections. Chemo-sensory muscle afferents showed increased responses to noxious chemical stimulation of their receptive fields in the PEGPH20 treated group. This was correlated with upregulation of the NGF receptor TrkA, the transient receptor potential vanilloid type 1 (TRPV1) channel and ATP-sensitive channel P2X3 in the DRG. Immunohistochemistry of hindpaw muscles revealed damage to the muscle architecture and extensive infiltration of the tissue by cells of the myelomonocytic lineage 3 days after PEGPH20 injection. Peripheral macrophage ablation in macrophage Fas-induced apoptosis (MaFIA) mice, however, did not prevent the decreased voluntary activity and instead caused even lower levels of running. These results suggest that disruption of hyaluronic acid within the muscle extracellular matrix sensitizes chemo-nociceptive muscle afferents possibly leading to altered pain-like behaviors. Ablation experiments suggest macrophages are necessary for adequate recovery of voluntary activity after hyaluronic acid (HA) disruption. These data support a role for HA and macrophages in tissue integrity and muscle pain development in patients taking PEGPH20.

Significance Statement:

Hyaluronidase co-administration has been suggested as a possible solution to improve the delivery of chemotherapeutic agents into difficult to access tissues. In clinical trials, patients receiving a systemic dose of hyaluronidase reported widespread pain as a side effect. Delivering hyaluronidase to mice, we found that they experienced decreased voluntary activity. We observed alterations in the response properties of metabo-nociceptive muscle afferents, accompanied by increased muscle infiltration of myeloid lineage cells including macrophages. Macrophage depletion at the time of hyaluronidase administration surprisingly exacerbated the decrease in voluntary activity. This suggests that increased hyaluronidase levels can affect muscle function and lead to immune responses, but also suggest these cells may be needed for muscle recovery to allow animals to perform activity-based tasks.

Introduction:

Pain is a frequent, undesired effect of pharmacotherapies aimed at treating different conditions. In the case of therapeutics used for cancer, long lasting pain is a major problem. Recent studies have explored the use of a novel approaches to cancer therapeutics, such as the disruption of the tumoral stroma. One of the suggested approaches to achieve disruption of the tumor microenvironment includes the use of a pegylated recombinant human hyaluronidase (PEGPH20) to target hyaluronic acid (HA), a major component of the tumoral extracellular matrix. Initial, phase Ib trials exploring the use of this strategy in patients with pancreatic cancer, however, reported musculoskeletal pain as well as extremity pain accompanied by edema and fatigue as the most common PEGPH20-related adverse events (Hingorani et al., 2016). At sufficient doses (1mg/Kg), PEGPH20 increased the entry of therapeutic antibodies into the tumor

93	stroma (Manuel et al., 2015; Singha et al., 2015; Li et al., 2018). Thus, it is important to
94	characterize the mechanism behind the observed side effects in order to maximize the potential
95	benefits of this approach.
96	
97	Hyaluronic acid is an important component of the extracellular matrix (ECM) within the skeletal
98	muscles. It has been localized to the epimysium, perimysium, and endomysium (Laurent et al.,
99	1991; Piehl-Aulin et al., 1991). It has also been associated with the perivascular and perineural
100	connective tissue (Laurent et al., 1991; Piehl-Aulin et al., 1991). In contrast, smooth muscle
101	seems almost devoid of HA (Laurent et al., 1991). As such, HA plays an important role in
102	maintaining the healthy architecture of skeletal muscle. A previous report has shown that HA car
103	be pro- or anti- nociceptive when injected in the skin, depending on its molecular weight (Ferrari
104	et al., 2016). Low molecular weight HA, a subproduct of hyaluronidase activation and
105	subsequent degradation of ECM HA during injury and inflammation, seems to be pronociceptive
106	(Ferrari et al., 2016; Ferrari et al., 2018). Contrary to this, high molecular weight HA can be
107	antinociceptive and ameliorate inflammatory pain (Ferrari et al., 2018; Bonet et al., 2020).
108	Regardless of their opposing functions, both forms seem to be related to activation of the CD44
109	receptor in sensory neurons.
110	
111	In contrast with the adverse effects reported in cancer patients, hyaluronidase has been used as a
112	therapeutic agent to treat upper limb muscle stiffness in individuals with cerebral injury
113	(Raghavan et al., 2016), without clinically significant side effects. The potential therapeutic
114	benefit has also been reported in patients with myofascial pain syndrome (Ghasemi et al., 2020).
115	These reports showing results in opposition to the adverse effects observed in larger clinical

116	trials in cancer patients, highlight the need to better understand the effects of systemic
117	administration of hyaluronidases in the skeletal muscles and the mechanisms behind its effects
118	on musculoskeletal pain.
119	
120	In order to develop strategies to ameliorate the pain-related adverse effects of the administration
121	of hyaluronidase, we explored the effects of systemic PEGPH20 administration in mice. Our
122	working hypothesis was that intraperitoneal (i.p.) administration of PEGPH20 will induce
123	widespread muscle pain potentially due to disruption of the normal muscle architecture that
124	affects the sensory processing. To test this, we used a wheel running activity assay, along with
125	evoked withdrawal to muscle squeezing, and grip strength, known methods to evaluate painful
126	responses from the muscles in mice (Tappe-Theodor et al., 2019; Contreras et al., 2021) to
127	examine the effects of PEGPH20 administration. We verified the effects of PEGPH20 on muscle
128	architecture via immunohistochemical staining of the hindpaw muscles and evaluated potential
129	changes in afferent function using a muscle-nerve-dorsal root ganglia-spinal cord ex-vivo
130	preparation and realtime PCR on affected DRGs.
131	
132	
133	Methods:
134	Animals
135	Experiments were conducted with young adult male mice (3–8 wks) of the following
136	backgrounds: C57BL/6J (C57), B6.129P2-Lyz2 ^{tm1(cre)Ifo} /J (LysMcre), B6.Cg-
137	$Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/J\ (tdTom),\ C57BL/6-Tg(Csf1r-EGFP-tdTomato)Hze/J\ (tdTom),\ C57BL/6-Tg(Csf1r-EGFP-tdT$
138	NGFR/FKBP1A/TNFRSF6)2Bck/J also known as macrophage fas-induced apoptosis (MaFIA)
139	mice (The Jackson Laboratory, Bar Harbor, ME) and littermate controls. All animals were

140	housed in a barrier facility in group cages of no more than 4 mice, maintained on a 12:12-h light-
141	dark cycle with a temperature-controlled environment, and given food and water ad-libitum. All
142	procedures were approved by the [Author Institution] Institutional Animal Care and Use
143	Committee and adhered to NIH Standards of Animal Care and Use under AAALAC approved
144	practices.
145	
146	Administration of PEGPH20 and AP compound
147	A single dose of PEGPH20 or its vehicle solution (10nM Histidine, 130nM NaCl, pH 6.5)
148	(provided by Halozyme, Inc.) was administered at a dose of 1mg/kg i.p.; the same effective dose
149	used in clinical trials (Li et al., 2018). The designer drug AP20187 (AP) was administered to the
150	MaFIA mice i.p. for seven days at a dose of 10 mg/kg for experiments utilizing these animals.
151	
152	Evoked pain-related behaviors
153	Testing of pain-related behaviors, withdrawal thresholds to muscle squeezing and grip strength,
154	have been performed previously (Ross et al., 2014; Queme et al., 2016; Queme et al., 2020).
155	Mice were first tested at baseline, as well as 1, 3, 5, and 7 days after the administration of either
156	PEGPH20 or vehicle, which were administered immediately after the baseline measurements.
157	
158	Mechanical withdrawal thresholds were determined by squeezing the hindpaw muscle with a
159	modified Paw Pressure Meter (World Precision Instruments, Sarasota, FL), fitted with a rounded
160	blunt probe that applied pressure to the plantar surface in order to stimulate deeper tissues. The
161	withdrawal threshold was recorded for 3 trials with 5-minute intervals between stimulations, and
162	the average was used for analysis. Muscle strength was tested via a grip strength meter (BioSeb,

Vitrolles, France). Animals were held by the tail over a metal bar while support was provided for the forepaws in order to measure grip strength exclusively on the hindpaw. Once the animal firmly held the bar with its hind paws, they were quickly pulled back horizontally (along the axis of the force sensor) until they could not retain their grip. Grip strength was measured (in g) in 3 rounds of 3 trials each, with 5 minutes between each round. The average of the nine trials was used for analysis.

Wheel running protocol

Animals were transferred from home cages to new cages fixed with a voluntary wheel attachment (Lafayette Instruments). Animals were singly housed with free access to food and water. The animals used in these experiments were used solely for the acquisition of voluntary wheel running behaviors and were not used for any measurements of pain-like behaviors or tissue analyses as previous literature (Grace et al., 2016; Ross et al., 2018) suggests a large role for voluntary wheel running on pain-like responses. For that same reason, voluntary activity was only monitored immediately after the administration of the PEGPH20 or vehicle, in an attempt to get a clear picture of the effects of the compound without the confounder of previous exercise. Either C57Bl/6 wildtype (WT) or MaFIA animals where used for these experiments. In groups treated with AP, seven daily IP injections (10 mg/kg) were administered 3 days prior to entry into the wheel cage and up to 4 days following entry. For all animals, PEGPH20 or vehicle was injected immediately before transfer to the wheel cages. Animals were housed in the wheel cages for seven days. Measurements obtained from voluntary running included numbers of revolutions, mean velocity (m/min) and distance travelled obtained in hourly bins.

Ex vivo recording preparation

Ex vivo recording was performed as previously described (Dourson et al., 2021). Briefly, mice were anesthetized with an intramuscular hindlimb injection of ketamine and xylazine (90 and 10 mg/kg, respectively) into the left leg and perfused transcardially with ice-chilled, oxygenated (95% O2-5% CO2) artificial cerebrospinal fluid (aCSF; in mM: 127.0 NaCl, 1.9 KCl, 1.2 KH2PO4, 1.3 MgSO4, 2.4 CaCl2, 26.0 NaHCO3, and 10.0 D-glucose). The right hindpaw and the spinal cord (SC) were then excised and placed in a bath of the same aCSF. The skin was removed along with the cutaneous branches of all the nerves. The SC was hemisected and the tibial nerve along with the distal hindlimb muscles innervated by this nerve (with bone left intact), were dissected in continuity with their respective DRGs (L5, L4 and L3). After dissection, the preparation was transferred to a separate recording chamber containing cold oxygenated aCSF. The paw was pinned on an elevated platform, keeping the entire paw perfused in a chamber isolated from the DRGs and the SC. Finally, the bath was slowly warmed to 32°C before recording from the DRGs.

All single unit recordings were made from the L3 and L4 DRGs. Sensory neuron somata were impaled with quartz microelectrodes (impedance>150M Ω) containing 5% Neurobiotin (Vector Laboratories, Burlingame, CA) in 1M potassium acetate. Electrical search stimuli were delivered through a suction electrode on the tibial nerve to locate sensory neurons with axons in this nerve. The latency from the onset of this stimulus and the conduction distance between the DRG and the stimulation site (measured directly along the nerve), were used to calculate the conduction velocity (CV) of the fibers. Group IV afferents were classified as those with a CV \leq 1.2 m/s, and group III afferents were those with CVs between 1.2 and 15 m/s. Peripheral receptive fields

(RFs) in the muscles were localized by electrically stimulating the muscles with a concentric
bipolar electrode. Only driven cells with RFs in the muscles then underwent mechanical,
thermal, and chemical testing. Mechanical response characteristics were assessed with an
increasing series of von Frey hairs ranging from 0.4 g to 10 g (with diameters of 0.23–0.36 mm).
Mechanical stimulation of the RF was held for approximately 1-2 seconds. Thermal responses
were determined by applying hot (≥50°C) or cold (≤3°C) saline directly to the paw muscles at
the electrically determined RF. Each application lasted ~1-2s. After that, the muscles were
exposed to an oxygenated "low" metabolite mixture (15 mM lactate, 1 μ M ATP, pH 7.0) and
then to a "high" metabolite mixture (50 mM lactate, 5 μ M ATP, pH 6.6) (Jankowski et al 2013)
(Queme et al 2020). delivered by a valve controller with an in-line heater to maintain solutions
at bath temperature. ATP was added to the mixture immediately prior to delivery of metabolites.
Adequate recovery times (~20-30 s) were employed between stimulations. All elicited
responses were recorded digitally for off-line analysis (Spike2 software, Cambridge Electronic
Design). Because exposure to metabolites can alter the response properties of sensory neurons,
all mechanical and thermal stimuli were repeated after exposure to metabolites. To verify that the
quality of the recordings does not deteriorate though the duration of the experiment, responses
from afferents recorded at the beginning and end of the experiment were grouped within
conditions and compared. We did not detect significant differences between recorded units
recorded at the beginning vs the end of the experiment.

Immunohistochemistry

In order to evaluate the integrity of the extracellular matrix and skeletal muscle fibers, we injected mice with 200uL of Evans-blue dye (i.p., 1% in 0.9% sterile saline solution)

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

immediately before administration of PEGPH20. Evans-blue Dye has been used extensively to evaluate the integrity and permeability of the membrane of muscle fibers (Hamer et al., 2002). Wheat germ agglutinin (WGA) conjugated with FITC (Life Technologies, Eugene, OR) was used to co-stain the tissue to visualize the membranes in the skeletal muscle, as previously described (Kostrominova, 2011). Briefly, muscle tissue was embedded in Tissue-Tek O.C.T. compound (Sakura Finetek USA Inc., Torrance, CA), flash frozen in liquid nitrogen and sectioned at 10µM on a cryostat and mounted on slides. Tissue was fixed on slide using 4% PFA in 0.1 M phosphate buffered saline (PBS). The samples were subsequently washed, blocked in 0.01M PBS containing 5% horse serum, 1% bovine serum albumin and 0.2% TritonX-100 for 10 min. Sections were stained with WGA-FITC (1:100), incubated for an hour, washed and cover slipped. A separate set of muscle samples from mice expressing a florescent reporter (tdTomato) on cells of myelomonocytic lineage (macrophages) were co-stained with Dystrophin (rabbit antidystrophin 1:250; Abcam, cat. No. ab15277), incubated overnight and labeled with secondary antibodies (AlexaFluor 488, 1:400; Jackson immunoresearch Laboratories, West Grove, PA) and cover slipped. Exposure time during microscopic analysis for each image was performed at the same intensity level to confirm staining above background. Distribution of fluorescent staining was determined with a Nikon confocal microscope with sequential scanning to avoid bleedthrough of the fluorophores. Images were captured at 40X magnification. 3 nonconsecutive sections, separated at least by 4 sections, from 3 different animals per condition were used to quantify the percentage of myofibers positive for EBD. All the muscle cells in a section were labeled using image J and muscle cells that were observed to contain red staining were considered positive. The percentage of positive cells obtained from each animal was used for comparisons. Similar methods were used to quantify LysM;tdTom cells in the muscle.

Macrophage ablation after AP compound administration was confirmed via confocal imaging of
the full hindpaw of the mouse. As before, 3 nonconsecutive sections from 3 different animals per
condition were used to quantify the area covered by GFP signal via ImageJ software. Minimum
intensity threshold was set at 60 and maximum at 255. Average intensity per animal was
determined among the 3 sections and data was then averaged across animals per group for
comparisons. Images for publication were prepared using Photoshop Elements software (Adobe,
San Jose, CA, USA).
RNA Isolation and Realtime PCR
DRG (L3-L4, right side) tissue was collected from PEGPH20, or vehicle treated conditions at
different time points. Tissue RNA was isolated using the Qiagen RNeasy kit, according to the
manufacturer's protocol. Fort realtime PCR, 500ng of total RNA was DNAse I treated
(Invitrogen) and reverse transcribed using Superscript II (Invitrogen) reverse transcriptase. 20ng
of cDNA were used in SYBR Green realtime PCR reactions that were performed in duplicate
and analyzed on a Step-One realtime PCR machine (Applied Biosystems).
Primer sequences for GAPDH, ASIC3, TRPV1, TRPA1, TrkA, GFRα3 were obtained from Elitt
et al. (Elitt et al., 2006). Primer sequences used for GFR α 1, GFR α 2, and P2X3 were obtained
from Jankowski et al. (Jankowski et al., 2009). Primer sequences for IL1r1 and P2X5 have been
reported previously (Ross et al., 2014). Cycle time (Ct) values for all targets were all normalized
to a GAPDH internal control. Ct values (used to determine fold change after injury) were then
obtained by subtracting the normalized target gene's Ct value from naive controls. Then fold

change was determined as $2^{\Delta\Delta Ct}$ (Applied Biosystems). The error of the difference in means is

then also calculated for the fold-change. Values were then converted and reported as a percent change where 2-fold change = 100% change.

Statistical analysis

All values are presented as mean \pm SEM unless stated differently. Behavioral assays, RT qPCR data, and comparisons of electrophysiological responses were tested with a 1-way ANOVA, or a 2-way repeated measures (RM) ANOVA with Bonferroni's post hoc test when appropriate. Two group comparisons that failed normality tests were tested with a Mann-Whitney U-test. Percentage of EBD positive cells was compared using a Chi-square test. Critical significance level was set at p<0.05.

Statistics table

	Data Structure	Type of test	Comparison	95%
				Confidence
				interval
a	Normally	Two-way RM		
	distributed	ANOVA		
		Bonferroni	PEGPH20 vs API	368.4 to 7286
		post-hoc test	Buffer Day 1	
		Bonferroni	PEGPH20 vs API	67.36 to 6985
		post-hoc test	Buffer Day 2	
		Bonferroni	PEGPH20 vs API	695.6 to 7613
		post-hoc test	Buffer Day 3	
b	Normally	Two-way RM		

	distributed	ANOVA		
		Bonferroni	PEGPH20 vs	11.85 to 146.1
		post-hoc test	Vehicle Day 5	
С	Normally	Two-way RM	Bonferroni post-	-8.005 to 12.52
	distributed	ANOVA	hoc test	
d	Non-normally	Kruskal-		Test does not
	distributed	Wallis test		generate
				confidence
				interval
e	Non-normally	Mann		-1.000 to 3.000
	distributed	Whitney U-		
		test		
f	Non-normally	Mann		-1.000 to 2.000
	distributed	Whitney U-		
		test		
g	Non-normally	Mann		-80.66 to 89.10
	distributed	Whitney U-		
		test		
h	Non-normally	Mann		1.700 to 24.62
	distributed	Whitney U-		
		test		
i	Non-normally	Mann		-12.70 to 24.30
	distributed	Whitney U-		

		test		
j	Non-normally	Mann		1.700 to 24.62
	distributed	Whitney U-		
		test		
k	Normally	Chi-square		Test does not
	distributed	test		generate
				confidence
				interval
1	Normally	Unpaired T-		22155 to 108900
	distributed	test		108900
m	Normally	Mixed-effects	PEGPH20 vs	-7169 to -963.0
	distributed	analysis	Vehicle Day 1	
		Bonferroni	PEGPH20 vs	-6877 to -456.6
		post-hoc test	Vehicle Day 2	
		Bonferroni	PEGPH20 vs	-8772 to -279.7
		post-hoc test	Vehicle Day 3	
		Bonferroni	PEGPH20 vs	110.9 to 2674
		post-hoc test	PEGPH20+AP	
			Day4	
		Bonferroni	PEGPH20 vs	309.0 to 2507
		post-hoc test	PEGPH20+AP	
			Day 5	
		Bonferroni	PEGPH20 vs	389.1 to 3866

	ı		T === =====	Г
		post-hoc test	PEGPH20+AP	
			Day 6	
		Bonferroni	PEGPH20 vs	580.0 to 3549
		post-hoc test	PEGPH20+AP	
			Day 7	
n	Normally	One-way RM		
	distributed	ANOVA		
		Bonferroni	PEGPH20 vs	395.7 to 2221
		post-hoc test	PEGPH20+AP	
		Bonferroni	PEGPH20 vs	-4459 to -2177
		post-hoc test	Vehicle	
		Bonferroni	PEGPH20+AP vs	-5256 to -3997
		post-hoc test	Vehicle	
		Bonferroni	AP vs Vehicle	1464 to 4666
		post-hoc test		

293

294

295

296

290 Results:

291 PEGPH20 induces long lasting reductions in voluntary activity as well as increased pain-

292 related behaviors.

Based on previous reports, we evaluated the effect of PEGPH20 on the activity levels of uninjured mice. To do this we administered PEGPH20 or vehicle solution at 1mg/kg i.p. The mice injected with vehicle ran approximately the same distance every day, preferentially during the night phase of the illumination cycle. Immediately after the administration of PEGPH20, the

mice showed significantly lower activity than their vehicle injected counterparts (Fig 1A ^a).
Activity remained significantly lower during the first 3 days after the administration of
PEGPH20 and did not recover to the same level of activity observed in vehicle treated animals
during the testing period.
In separate cohorts of mice, we tested pain related behaviors 1 day before the administration of
PEGPH20 or vehicle and continued testing 1 day after the administration and every other day up
to 7 days (Fig 1B ^b). We did not detect any changes in the mechanical withdrawal thresholds to
muscle squeezing at 1, and 3 days after compound administration. In contrast, 5 days after the
administration of PEGPH20 there was a significant decrease in the mechanical withdrawal
threshold. This decrease in withdrawal threshold reversed 7 days after PEGPH20 administration
Finally, we tested grip strength in the hind paws. While the mean grip strength increased slowly
after day 1 (Fig 1C ^c), both groups followed the same pattern and there were not significant
differences between the group that received PEGPH20 or the group that received vehicle.
PEGPH20 induces changes in the response properties of primary sensory neurons to a
noxious combination of metabolites.
Using an ex-vivo muscle-nerve-DRG-spinal cord preparation, we performed single unit
recordings from afferents innervating the right hindpaw muscles at 1 and 3 days after the
administration of PEGPH20 or vehicle. Preliminary analysis did not reveal differences between
the recordings captured at 1 or 3 days for both groups as shown in Table 1 ^d , so both timepoints
were merged into one group for each condition. As shown in Fig 2A,B ^{e,f} , we did not find any

significant differences in the afferent response properties to mechanical stimulation. No changes

in either threshold, instantaneous frequency (IF), or firing rate (FR) were observed between
conditions. There were also no significant differences in the responses to heat or cold stimulation
(Fig 2C, D ^{g,h}). However, when we stimulated the preparation with different concentrations of
metabolites (lactate, ATP, and low pH) resembling the environment in the muscle during normal
work-related activity (Low metabolites) or ischemic contractions (High metabolites), we found
no differences in the response pattern to the low concentration of metabolites, but found an
increased response of group III/IV afferents (IF) to higher concentrations of these metabolites in
the group that was treated with PEGPH20 compared with vehicle treated controls (Fig 2E,F ^{i,j}).
PEGPH20 causes a breakdown of the membranes within the muscle as well as an increased
infiltration by LysM-tdTom cells.
The target of PEGPH20 is hyaluronic acid (HA), an important structural component of the
architecture of skeletal muscle. We suspected that the effects of PEGPH20 on voluntary activity
and response properties of skeletal muscle afferents could be explained by changes in the
structure of the muscle. As shown in Figure 3A,B ^k , 1 day after the administration of PEGPH20,
we observed widespread staining of the muscle tissue with Evans-blue dye, suggesting a
disruption of the membranes within the skeletal muscles. In the mice treated with vehicle, there
is very low Evans-blue leakage into the muscle.
Tissue injury has frequently been associated with increased infiltration of the affected tissue by
immune cells. In particular, macrophages are known to play an important role not only in the
development of muscle pain in other models but have also been suggested to play an important

role in the subsequent repair of the injured tissue. In order to evaluate if macrophages could be

343	playing a role in the increased musculoskeletal pain secondary to PEGPH20 administration, we
344	administered PEGPH20 to mice expressing a fluorescent reporter protein in cells of
345	myelomonocytic lineage (LysMcre/TdTomato mice). 3 days after the administration of
346	PEGPH20, we observed widespread infiltration of myeloid lineage cells into skeletal muscle
347	(Fig. 3C) compared with little infiltration in the vehicle treated animals (Veh: 3.9±1.9 vs
348	PEGPH20: *32± 3.4; t=6.46, df=4; *p<0.003, t-test).
349	
350	To better understand the effects of the alterations in the musculoskeletal structure in the changes
351	observed in response properties of primary muscle afferents, we isolated RNA from whole DRGs
352	(L3 and L4) and performed realtime PCR. We tested for a variety of genes at 1 day after
353	PEGPH20 administration. We did not observe significant changes in gene expression 1 day after
354	PEGPH20 administration. 3 days after injection of PEGPH20, however, we observed a
355	significant upregulation in the P2X receptor 3 (P2X3), and a decrease in the expression of the
356	GDNF receptor, GFRα1 and the Interleukin-1 receptor IL-1r1. By day 5 we observed a
357	significant decrease in the expression of the NGF receptor TrkA reverting the trend observed in
358	day 1 and day 3. No changes were observed at 7d with the exception of P2X3 which remained
359	elevated 7 days after injury (Table 2).
360	
361	Ablation of macrophages does not improve the effects of PEGPH20 on voluntary activity
362	Our previous observation of infiltration by cells of myelomonocytic lineage in the skeletal
363	muscle after PEGPH20 administration suggested that these immune cells may be playing a
364	significant role in the development of long-lasting muscle pain. To test if macrophages played
365	any role in the development of decreased voluntary activity after PEGPH20 administration, we

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

decided to ablate them in mice with PEGPH20 injection and assayed voluntary running. To do this, we used macrophage fas-induced apoptosis (MaFIA) mice. MaFIA mice are a transgenic line that, when injected with the designer drug AP20187 (AP) temporarily ablates peripheral macrophages and dendritic cells. Our injection protocol replicated the dose and scheme used in previous studies that showed evident macrophage depletion 24h after the third injection (Burnett et al., 2004). Other works using lower doses than our protocol report up to 90% depletion of circulating monocytes that does not recuperate until 4 days after the last dose of AP (Yu et al., 2020). We confirmed the effectiveness of this strategy via immunohistochemistry. MaFIA mice treated with PEGPH20 + AP compound had significantly less GFP signal in the hindpaw compared to PEGPH20 + Vehicle treated animals (Fig 4 A, B¹). This approach insured that macrophages were not present in the periphery at the time of PEGPH20 administration and that the macrophage population would not start to recover until after at least 5 days into the running experiment, allowing for the observation of the voluntary activity pattern of the mice when exposed to hyaluronidase, but lacking peripheral macrophage infiltration. We found that the injection of PEGPH20 reduced the distance that animals traveled in all groups compared to vehicle controls and that ablation of macrophages by injection of AP did not ameliorate the effects of PEGPH20. In fact, while animals injected with only PEGPH20 showed a small recovery of the traveled distance at days 6 and 7, the animals that received AP in combination with PEGPH20 did not show any recovery (Fig 4C^m). Administration of AP alone induced a significant decrease in activity compared to the vehicle treated mice and almost in line with the decrease observed after administration of PEGPH20 (Table 3). This suggests that macrophage depletion can have a big impact on mouse behavior and should always be considered when using MaFIA mice as a model. When we compared the total running distance

of mice injected with PEGPH20 or AP alone to the combination of both PEGPH20 and AP, the combination group showed an additive effect, reducing voluntary activity almost completely. We found that animals injected with both compounds ran significantly less than those injected with either one compound alone, as well as from controls (Fig. 4C^m, Dⁿ). This suggests that the presence of macrophages in the skeletal muscle after the disruption of the architecture by hyaluronidase administration may be protective and may be more important for the recuperation of the mice from hyaluronidase treatment than for the development of the decreased voluntary activity.

Discussion:

Pharmacological therapies for cancer frequently result in the undesired adverse effect of pain (Fallon, 2013; Masocha, 2018). As the search for novel therapeutic approaches expands, it is logical to expect different clinical presentations. Recently, therapies involving the administration of hyaluronidase systemically as a potential enhancer of chemotherapeutic approaches for pancreatic cancer have been explored (Hingorani et al., 2016). One of the observed adverse effects of this approach was widespread muscle pain (Hingorani et al., 2016). In contrast, in other clinical settings, hyaluronidase has been used successfully in ophthalmic surgery as an enhancer of local anesthesia (Buhren et al., 2016; Rüschen et al., 2018). The potential of the enzyme to disrupt connective tissue adhesions has led to the off-label use of this enzyme for the treatment of epidural adhesions associated with chronic back pain (Dunn et al., 2010) or to treat myofascial pain syndrome secondary to tissue contractures (Raghavan et al., 2016; Ghasemi et al., 2020). Recent reports have explored the specific role of HA in the sensitization of primary sensory neurons. Several reports suggest that high-molecular-weight HA (HMWHA) can reduce

inflammation-induced hyperalgesia (Ferrari et al., 2018; Bonet et al., 2020), while its counterpart, low-molecular-weight HA (LMWHA) is capable of inducing mechanical hyperalgesia (Ferrari et al., 2016). Furthermore, it has been reported that digestion of HMWHA by hyaluronidase produces LMWHA and that the later can inhibit the differentiation of monocytes that infiltrate tissue after injury into fibrocytes, cells that help in the repair of tissue after injury (Maharjan et al., 2011). These findings would be in line with our observations and would explain why the administration of PEGPH20 not only increases the recruitment of myeloid lineage cells such as macrophages into the affected muscle but would also explain why the removal of cells of myelomonocytic lineage aggravates the effects of PEGPH20 administration.

In this study, we aimed to further characterize the effects of systemic administration of PEGPH20 in the development of widespread pain and determine the contribution of muscle primary sensory neurons in this phenomenon. In accordance with clinical observations, our mice experienced an immediate decrease in voluntary wheel running after the administration of PEGPH20. Voluntary wheel running has been shown to be a reliable pain assessment tool in rodents (Ross et al., 2018; Kandasamy and Morgan, 2021) and has been shown to recuperate faster than evoked measurements, closely replicating the recovery observed in the clinical setting (Kandasamy et al., 2016). These differences between the results observed from voluntary running and the evoked pain-related behaviors (muscle squeezing), can explain why we are able to observe an acute drop in the activity, but we do not detect changes in withdrawal thresholds until 5 days after injection. It is also relevant that in our behavioral assessments, we did not observe a decrease in overall grip strength suggesting that the effects of PEGPH20 do not alter

the ability to forcefully contract muscles and that the differences in activity are more representative of pain-like effects under these specific conditions.

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

436

437

The lack of changes in the mechanical withdrawal thresholds at 1 and 3 days after PEGPH20 administration correlates very well with the observations in our electrophysiological recordings where we did not detect any differences in the response to mechanical stimulation between groups. Nevertheless, a limitation of this study lies in the fact that we did not perform electrophysiological studies at 5 days after PEGPH20 administration that would facilitate the understanding of the evoked behavioral changes observed a this timepoint. However, it is interesting that we detected a significant difference in the responses to stimulation with high metabolites, a combination of low pH, ATP and lactic acid that closely resembles the environment in the muscle during painful, ischemic muscle contractions (Light et al., 2008; Jankowski et al., 2009; Pollak et al., 2014; Ross et al., 2014; Queme et al., 2020). If this specific subset of afferents, thought to perform the function of metabo-nociceptors is sensitized, it is logical to expect that during intense muscle activity, the mice would experience increased pain and thus avoid voluntary exercise. Since the changes in activity were so robust and were detected very early on, it is likely that sensitization of these afferents is a larger driving force of HA induced pain in humans rather than changes in mechanical nociceptors. It is important to note that heat responsiveness in afferents is slightly, but not statistically increased after PEGPH20 treatment. A future study assessing greater numbers of heat sensitive afferent would be necessary however to determine this. Another important limitation of this study is that it was only performed in male mice. Several conditions presenting with chronic musculoskeletal pain,

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

perform these studies in females to assess sex differences in responses to PEGPH20. Multiple receptors have frequently been associated with the development of musculoskeletal pain. Some of the receptors that have been traditionally associated with increased pain include the NGF receptor TrkA (Hayashi et al., 2011; Queme et al., 2013; Oga et al., 2020) as well as the ion channel TRPV1. Contrary to our expectations, neither of these receptors showed increased expression after the administration of PEGPH20. In fact, TrkA it was significantly downregulated 5 days after the administration of hyaluronidase. While these results are indicative of directionality, it is worth noting that further experimentation is needed to understand if the mRNA expression profile observed after administration of PEGPH20 is also translated to protein levels (Schindler et al., 1990; Raqib et al., 1996; Donlin-Asp et al., 2021) Other receptors that have been frequently associated with the development of muscle pain in the context of ischemia, such as the interleukin 1 receptor, IL-1r1(Ross et al., 2016), and the GDNF receptor GFRa1 (Queme et al., 2020) were also found to be downregulated at several timepoints after the administration of PEGPH20. Previous studies have shown that ischemic injury of the muscle can induce upregulation of these receptors. It is plausible that direct injury of the muscle cells is necessary to cause this upregulation and that disruption of the extracellular matrix is causing sensitization of primary muscle afferents via a completely different mechanism. In contrast, the P2X3 receptor is known to be upregulated in the DRG after ischemic muscle injuries (Ross et al., 2014; Ross et al., 2016), and has been linked to inflammatory pain development (Queme et al., 2017). This receptor may therefore play a role in the development of pain and decreased voluntary activity in these experiments. As an ATP sensitive ion channel,

such as fibromyalgia, have a higher prevalence in females. It will therefore be important to

increased expression of P2X3 could be involved in the increased responses observed in the chemo-nociceptive muscle afferents.

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

481

482

The increased presence of myelomonocytic-lineage cells in the muscle tissue after PEGPH20 administration suggested an important role for these immune cells. We hypothesized that macrophage infiltration in the muscle may be playing a role in sensitizing primary muscle afferents as this has been shown in different models of musculoskeletal pain (Gong et al., 2016; Oliveira-Fusaro et al., 2020). We tested this by ablating the peripheral macrophage population during PEGPH20 administration. Contrary to our predictions, we did not observe a recuperation of the voluntary activity when we administered PEGPH20 in combination with AP. In fact, we observed a marked decrease in the total activity of the animals. Previous work has shown that after systemic depletion of macrophages, nerve injury related pain can be prevented (Yu et al., 2020). However, in that study, depletion of the macrophages infiltrating the DRG after nerve injury was required to prevent the development of pain. A recent study used a tourniquet-based model of complex regional pain syndrome (CRPS), to induce musculoskeletal pain and showed that depletion of macrophages could prevent the development of pain after ischemic injury (De Logu et al., 2020). These studies, show that macrophages are necessary for the development of musculoskeletal pain. In contrast with our observations, neither of the models used in the previous work, result in the disruption of the ECM and the potential generation of LMWHA that would be expected after the administration of hyaluronidase.

501

502

503

Other studies using the MaFIA mouse line have reported that AP compound administration can induce malaise, intra-abdominal tissue adhesion and weight loss in mice (Burnett et al., 2004; Yu

et al., 2020). Interestingly, we found that AP alone induced a significant decrease in the overall activity levels comparable to the effect of PEGPH20 alone. A previous study using the MaFIA mouse line found that systemic administration of AP could cause significant weight loss and increased baseline mechanical thresholds (Yu et al., 2020). In the current study, we observed an additive effect in MaFIA animals treated with AP and PEGPH20, where animals had overall lower activity than either group alone. These data and the previous work indicate that the removal of myeloid-lineage cells results in both acute mechanical alterations, as well as prolonged prevention of physical activity. However, future studies using these animals should consider assessing multiple parameters as weight, mechanical thresholds, and activity are all affected by monocyte/macrophage ablation.

Macrophages are also known to play an important role in tissue repair after injury (Wynn and Vannella, 2016). They play an important role in the initiation maintenance and resolution phases of tissue repair (Mantovani et al., 2013; Wynn and Vannella, 2016; Kim and Nair, 2019). As such, it is possible that instead of preventing the development of muscle pain, macrophage ablation prevented the resolution of pain after PEGPH20 administration. This result is an important consideration for future therapies that desire to target macrophage depletion for pain relief.

Overall, this study highlights how systemic administration of hyaluronidase can disrupt the architecture of skeletal muscle, inducing sensitization of primary muscle afferents and leading to pain-like behaviors. Under these conditions, macrophages may be playing an important role in the resolution of injury instead of driving the initiation of pain. Our results also point out at the

possibility that macrophages are needed to resolve damage to skeletal muscle and potential
therapies should not focus exclusively in removing or inhibiting macrophages but consider the
possibility of harnessing their injury resolving properties as potential therapeutic options.

531 References:

- Bonet IJM, Araldi D, Khomula EV, Bogen O, Green PG, Levine JD (2020) Mechanisms Mediating High Molecular-Weight Hyaluronan-Induced Antihyperalgesia. J Neurosci 40:6477-6488.
 - Buhren BA, Schrumpf H, Hoff NP, Bölke E, Hilton S, Gerber PA (2016) Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res 21:5.
 - Burnett SH, Kershen EJ, Zhang J, Zeng L, Straley SC, Kaplan AM, Cohen DA (2004) Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J Leukoc Biol 75:612-623.
 - Contreras KM, Caillaud M, Neddenriep B, Bagdas D, Roberts JL, Ulker E, White AB, Aboulhosn R, Toma W, Khalefa T, Adel A, Mann JA, Damaj MI (2021) Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype. Behav Brain Res 399:113009.
 - De Logu F, De Prá SD, de David Antoniazzi CT, Kudsi SQ, Ferro PR, Landini L, Rigo FK, de Bem Silveira G, Silveira PCL, Oliveira SM, Marini M, Mattei G, Ferreira J, Geppetti P, Nassini R, Trevisan G (2020) Macrophages and Schwann cell TRPA1 mediate chronic allodynia in a mouse model of complex regional pain syndrome type I. Brain Behav Immun 88:535-546.
 - Donlin-Asp PG, Polisseni C, Klimek R, Heckel A, Schuman EM (2021) Differential regulation of local mRNA dynamics and translation following long-term potentiation and depression. Proceedings of the National Academy of Sciences 118:e2017578118.
 - Dourson AJ, Ford ZK, Green KJ, McCrossan CE, Hofmann MC, Hudgins RC, Jankowski MP (2021) Early Life Nociception is Influenced by Peripheral Growth Hormone Signaling. J Neurosci 41:4410-4427.
 - Dunn AL, Heavner JE, Racz G, Day M (2010) Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert Opin Biol Ther 10:127-131.
 - Elitt CM, McIlwrath SL, Lawson JJ, Malin SA, Molliver DC, Cornuet PK, Koerber HR, Davis BM, Albers KM (2006) Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J Neurosci 26:8578-8587.
 - Fallon MT (2013) Neuropathic pain in cancer. Br J Anaesth 111:105-111.
 - Ferrari LF, Araldi D, Bogen O, Levine JD (2016) Extracellular matrix hyaluronan signals via its CD44 receptor in the increased responsiveness to mechanical stimulation. Neuroscience 324:390-398.
 - Ferrari LF, Khomula EV, Araldi D, Levine JD (2018) CD44 Signaling Mediates High Molecular Weight Hyaluronan-Induced Antihyperalgesia. The Journal of neuroscience: the official journal of the Society for Neuroscience 38:308-321.
 - Ghasemi M, Mosaffa F, Hoseini B, Behnaz F (2020) Comparison of the Effect of Bicarbonate, Hyaluronidase, and Lidocaine Injection on Myofascial Pain Syndrome. Anesth Pain Med 10:e101037.
 - Gong WY, Abdelhamid RE, Carvalho CS, Sluka KA (2016) Resident Macrophages in Muscle Contribute to Development of Hyperalgesia in a Mouse Model of Noninflammatory Muscle Pain. J Pain 17:1081-1094.
 - Grace PM, Fabisiak TJ, Green-Fulgham SM, Anderson ND, Strand KA, Kwilasz AJ, Galer EL, Walker FR, Greenwood BN, Maier SF, Fleshner M, Watkins LR (2016) Prior voluntary wheel running attenuates neuropathic pain. Pain 157:2012-2023.
 - Hamer PW, McGeachie JM, Davies MJ, Grounds MD (2002) Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 200:69-79.
 - Hayashi K, Ozaki N, Kawakita K, Itoh K, Mizumura K, Furukawa K, Yasui M, Hori K, Yi SQ, Yamaguchi T, Sugiura Y (2011) Involvement of NGF in the rat model of persistent muscle pain associated with taut band. J Pain 12:1059-1068.

- Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA,
 Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE (2016) Phase Ib
 Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with
 Advanced Pancreatic Cancer. Clin Cancer Res 22:2848-2854.
 - Jankowski MP, Rau KK, Ekmann KM, Anderson CE, Koerber HR (2013) Comprehensive phenotyping of group III and IV muscle afferents in mouse. J Neurophysiol 109:2374-2381.
 - Jankowski MP, Lawson JJ, McIlwrath SL, Rau KK, Anderson CE, Albers KM, Koerber HR (2009)

 Sensitization of cutaneous nociceptors after nerve transection and regeneration: possible role of target-derived neurotrophic factor signaling. J Neurosci 29:1636-1647.
 - Kandasamy R, Morgan MM (2021) 'Reinventing the wheel' to advance the development of pain therapeutics. Behav Pharmacol 32:142-152.
 - Kandasamy R, Calsbeek JJ, Morgan MM (2016) Home cage wheel running is an objective and clinically relevant method to assess inflammatory pain in male and female rats. J Neurosci Methods 263:115-122.
 - Kim SY, Nair MG (2019) Macrophages in wound healing: activation and plasticity. Immunol Cell Biol 97:258-267.
 - Kostrominova TY (2011) Application of WGA lectin staining for visualization of the connective tissue in skeletal muscle, bone, and ligament/tendon studies. Microsc Res Tech 74:18-22.
 - Laurent C, Johnson-Wells G, Hellström S, Engström-Laurent A, Wells AF (1991) Localization of hyaluronan in various muscular tissues. A morphological study in the rat. Cell Tissue Res 263:201-205.
 - Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, Thompson CB (2018) Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res 24:4798-4807.
 - Light AR, Hughen RW, Zhang J, Rainier J, Liu Z, Lee J (2008) Dorsal root ganglion neurons innervating skeletal muscle respond to physiological combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1. J Neurophysiol 100:1184-1201.
 - Maharjan AS, Pilling D, Gomer RH (2011) High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS One 6:e26078.
 - Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176-185.
 - Manuel ER, Chen J, D'Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, Ludwig T, Chung V, Diamond DJ (2015) Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res 3:1096-1107.
 - Masocha W (2018) Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models. Pain Res Manag 2018:5234943.
 - Oga S, Goto K, Sakamoto J, Honda Y, Sasaki R, Ishikawa K, Kataoka H, Nakano J, Origuchi T, Okita M (2020) Mechanisms underlying immobilization-induced muscle pain in rats. Muscle Nerve 61:662-670.
 - Oliveira-Fusaro MC, Gregory NS, Kolker SJ, Rasmussen L, Allen LH, Sluka KA (2020) P2X4 Receptors on Muscle Macrophages Are Required for Development of Hyperalgesia in an Animal Model of Activity-Induced Muscle Pain. Mol Neurobiol 57:1917-1929.
 - Piehl-Aulin K, Laurent C, Engström-Laurent A, Hellström S, Henriksson J (1991) Hyaluronan in human skeletal muscle of lower extremity: concentration, distribution, and effect of exercise. J Appl Physiol (1985) 71:2493-2498.

626	Poliak KA, Swenson JD, Vannaitsma TA, Hughen KW, Jo D, White AT, Light KC, Schweinhardt P, Amann
627	M, Light AR (2014) Exogenously applied muscle metabolites synergistically evoke sensations of
628	muscle fatigue and pain in human subjects. Exp Physiol 99:368-380.
629	Queme F, Taguchi T, Mizumura K, Graven-Nielsen T (2013) Muscular heat and mechanical pain
630	sensitivity after lengthening contractions in humans and animals. J Pain 14:1425-1436.
631	Queme LF, Ross JL, Jankowski MP (2017) Peripheral Mechanisms of Ischemic Myalgia. Front Cell
632	Neurosci 11:419.
633	Queme LF, Ross JL, Lu P, Hudgins RC, Jankowski MP (2016) Dual Modulation of Nociception and
634	Cardiovascular Reflexes during Peripheral Ischemia through P2Y1 Receptor-Dependent
635	Sensitization of Muscle Afferents. Journal of Neuroscience 36:19-30.
636	Queme LF, Weyler AA, Cohen ER, Hudgins RC, Jankowski MP (2020) A dual role for peripheral GDNF
637	signaling in nociception and cardiovascular reflexes in the mouse. Proc Natl Acad Sci U S A
638	117:698-707.
639	Raghavan P, Lu Y, Mirchandani M, Stecco A (2016) Human Recombinant Hyaluronidase Injections For
640	Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series. EBioMedicine
641	9:306-313.
642	Raqib R, Ljungdahl A, Lindberg AA, Wretlind B, Andersson U, Andersson J (1996) Dissociation between
643	cytokine mRNA expression and protein production in shigellosis. Eur J Immunol 26:1130-1138.
644	Ross JL, Queme LF, Shank AT, Hudgins RC, Jankowski MP (2014) Sensitization of group III and IV muscle
645	afferents in the mouse after ischemia and reperfusion injury. J Pain 15:1257-1270.
646	Ross JL, Queme LF, Lamb JE, Green KJ, Ford ZK, Jankowski MP (2018) Interleukin 1β inhibition
647	contributes to the antinociceptive effects of voluntary exercise on ischemia/reperfusion-induce
648	hypersensitivity. Pain 159:380-392.
649	Ross JL, Queme LF, Cohen ER, Green KJ, Lu P, Shank AT, An S, Hudgins RC, Jankowski MP (2016) Muscle
650	IL1β Drives Ischemic Myalgia via ASIC3-Mediated Sensory Neuron Sensitization. J Neurosci
651	36:6857-6871.
652	Rüschen H, Aravinth K, Bunce C, Bokre D (2018) Use of hyaluronidase as an adjunct to local anaesthetic
653	eye blocks to reduce intraoperative pain in adults. Cochrane Database Syst Rev 3:Cd010368.
654	Schindler R, Clark BD, Dinarello CA (1990) Dissociation between interleukin-1 beta mRNA and protein
655	synthesis in human peripheral blood mononuclear cells. J Biol Chem 265:10232-10237.
656	Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, Huang Z, Shepard HM (2015) Tumor-
657	associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther 14:523-
658	532.
659	Tappe-Theodor A, King T, Morgan MM (2019) Pros and Cons of Clinically Relevant Methods to Assess
660	Pain in Rodents. Neurosci Biobehav Rev 100:335-343.
661	Wynn TA, Vannella KM (2016) Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity
662	44:450-462.
663	Yu X, Liu H, Hamel KA, Morvan MG, Yu S, Leff J, Guan Z, Braz JM, Basbaum AI (2020) Dorsal root ganglion
664	macrophages contribute to both the initiation and persistence of neuropathic pain. Nat
665	Commun 11:264.
666	
667	
668	


670	Figure legends:
671	Figure 1. PEGPH20 decreases voluntary wheel running but does not cause acute
672	mechanical hypersensitivity. A. Voluntary wheel running is significantly decreased up to 3
673	days after the administration of PEGPH20 (n=12), compared to vehicle controls (n=12). B.
674	Withdrawal thresholds to muscle squeezing are significantly lower 5 days after the
675	administration of PEGPH20 (n=8) compared to vehicle treated mice (n=8). C. There are no
676	significant differences in grip strength between mice treated with PEGPH20 (n=8) vs vehicle
677	treated mice (n=8). Two-way RM ANOVA (Bonferroni post-hoc); A. F(1,14)=6.654, p=0.218
678	B. F(4,56)=5.515, p=0.0008; C. F(4,56)=0.68. A-C *p<0.05. **p<0.01 vs vehicle.
679	
680	Figure 2. PEGPH20 induces increased response to noxious metabolites in metabo-
681	nociceptive primary muscle afferents. A-D. We did not observe changes in the mechanical
682	thresholds or response patterns of mechanically sensitive neurons after PEGPH20 (n= 18)
683	administration, compared to vehicle controls (n=18). The same can be said of the responses to
684	heat (n=3 per group) or cold (n=4 per group) stimulation. E-F. While there were no changes in
685	the response to chemical stimulation in neurons sensitive to a low concentration of metabolite
686	(Vehicle, n=5; PEGPH20 n=12), injection of PEGPH20 caused a significant increase in the
687	instantaneous frequency of firing in high metabolite responsive neurons (metabo-nociceptors)
688	(Vehicle n=8, PEGPH20 n=9). G. Representative traces of mechanical, thermal, and chemical
689	responses from neurons recorded from either Vehicle or PEGPH20 treated mice. Arrows
690	represent application of stimulus. A-F Mann Whitney U-test, *p<0.02 vs vehicle.


Figure 3. PEGPH20 disrupts of skeletal muscle architecture that is accompanied by			
macrophage infiltration. A. Muscle extracellular membrane (green - WGA) is disrupted 3 days			
after the administration of PEGPH20. EBD (red) usually remains in intravascular spaces in intact			
tissue but after hyaluronidase administration it leaks into the affected skeletal muscle. B.			
Percentage of myofibers positive for EBD 3 days after PEGPH20 administration. C. At the same			
timepoint macrophages (red - LysM/tdTomato) infiltrate the connective tissue surrounding the			
skeletal muscle in contrast to the almost non-present macrophages in the vehicle treated animals.			
White scale bar is $50\mu m$. ***p<0.001 χ^2 test.			
Figure 4. Ablation of macrophages does not prevent decreased voluntary wheel running			
after administration of PEGPH20. A. Administration of AP for 7 days starting 3 days before			
PEGPH20 injection removes macrophages from all hindpaw tissues as revealed by the lack of			
GFP signal (arrows) in the treated animals compared to vehicle treated controls. B.			
Quantification of GFP signal reveals significantly less signal in AP-treated mice (n=3) vs			
Vehicle-treated animals (n=3). Ablation of macrophages in MaFIA mice does not prevent the			
development of decreased voluntary wheel running distance after PEGPH20 (n=12)			
administration compared to vehicle treated mice (n=12). In fact, the combination of			
PEGPH20+AP (n=8) used to ablate macrophages prevents the slow recuperation that initiates			
around 4 days after PEGPH20 administration. B. Total wheel running distance is significantly			
lower in PEPH20, AP alone (n=8), or PEGPH20+AP treated mice compared to just vehicle			
treated mice. The total running distance of PEGPH20+AP treated mice was also significantly			
lower than in animals treated with just PEGPH20 or AP alone. White scale bar is 50 $\mu M\ B.$			


Unpaired T-test; C. Mixed-effects analysis (F (2,29) = 19.16, p<0.0001) with Bonferroni post-


715	hoc; D. One-way ANOVA (F $(3,24) = 38.87$, p<0.001) with Bonferroni post-hoc. #p<0.05,
716	^p<0.01 vs PEGPH20+AP; *p<0.05, **p<0.01 vs vehicle.
717	
718	
719	
720	Table 1: General electrophysiological parameters from recordings 1 and 3 days after
721	administration of PEGPH20 or Vehicle. We do not observe any significant differences
722	between electrophysiological recordings performed either 1 or 3 days after treatment in each
723	condition.
724	
725	Table 2: Select DRG gene expression after PEGPH20 administration (1-7 days). Values
726	indicate % change vs vehicle treated controls. Mean \pm SEM. n=4 per group per time point. One-
727	way ANOVA (TrkA F(4,14)=10.57, p=0.0004; P2X3 F(4,14)=17.27, p<0.0001; GFR α 1
728	F(4,13)=29.57, p<0.0001; LI1r1 F(4,12)=8.272, p=0.0019) with Bonferroni post-hoc. * p<0.05,
729	** p<0.01, *** p<0.001 vs vehicle treated controls. GAPDH CT (mean \pm SEM) CTRL: 20.97 \pm
730	0.26 ; D1 19.651 ± 0.07 ; D3 20.295 ± 0.45 D5 21.2 ± 0.39 D7 22.32 ± 0.82 . No significant
731	differences were detected between the CTRL or treatment groups (One-way ANOVA
732	F(4,14)=3.8, p=0.026).
733	
734	Table 3: Total daily distance traveled after treatment. Administration of AP alone (n=6)
735	induced changes similar to Vehicle (n=8), PEGPH20 (n=12), and PEGPH20+AP (n=12). The
736	combination of PEGPH20+AP produced significantly lower levels of activity during the first 4
737	days after administration but did not show the recuperation observed by 7 days in both the


- 738 PEGPH20 or AP alone treated groups. Data from AP alone for day 3 only includes n=2 due to
- 739 equipment failure that did not allow capture of data for the single time point. 2-way ANOVA,
- 740 F(3,34)=12.54, p<0.0001 with Bonferroni post hoc test. *p<0.05, **p<0.01 vs Vehicle, #p<0.05
- 741 vs PEGPH20.

















	Condition		
Table 1	Vehicle 1d	Vehicle 3d	
Conduction	10.56 ± 1.99	6.71 ± 1.37	
Velocity	(n=27)	(n=21)	
Mechanical Threshold	2.77 ± 1.08	4.29 ± 1.52	
Mechanical Threshold	(n=9)	(n=7)	
Mechanical response	44.02 ± 18.57	108.80 ± 50.19	
(Peak IF, Hz)	(n=9)	(n=7)	
Heat response	3.03 ± 0.95	4.7 ± 0.0	
(Peak IF, Hz)	(n=2)	(n=1)	
Cold response	63.53 ± 18.53	34.90 ± 33.20	
(Peak IF, Hz)	(n=2)	(n=2)	
Low Metabolite response	13.4 ± 0.0	26.58 ± 23.24	
(Peak IF, Hz)	(n=1)	(n=4)	
Hight Metabolite response	1.39 ± 0.64	8.37 ± 6.19	
(Peak IF, Hz)	(n=3)	(n=4)	
	Conc	lition	
	PEGPH20 1d	PEGPH20 3d	
Conduction	6.487 ± 1.18	10.33 ± 1.92	
Velocity	(n=24)	(n=24)	
Mechanical Threshold	5.2 ± 1.11	1.92 ± 1.17	
Machaniaal magnana	(n=9) 77.41 ± 9.95	(n=7) 88.07 ± 31.53	
Mechanical response (Peak IF, Hz)	(n=9)		
Heat response	(n-9) 26.7 ± 0.0	(n=7) 7.9 ± 1.5	
(Peak IF, Hz)	(n=1)	(n=2)	
Cold response	No cold responses	39.48 ± 18.73	
(Peak IF, Hz)	recorded	(n=4)	
Low Metabolite response	3.9 ± 1.45	30.66 ± 12.09	
(Peak IF, Hz)	(n=5)	(n=7)	
Hight Metabolite response	13.16 ± 4.62	37.82 ± 14.05	
(Peak IF, Hz)	(n=4)	(n=5)	

Table 2

Gene	<u>D1</u>	<u>D3</u>	<u>D5</u>	<u>D7</u>
TrkA	21.9 ± 13.5	70.2 ± 8.0	-60.7 ± 13.4*	-52.2 ±30.3
P2X3	49.8 ± 13.1	458.3 ± 13.8***	114.8 ± 29.2	459.6 ± 25.9**
P2X5	-4.4 ± 10.2	-63.9 ± 39.1	-37.0 ± 38.9	-62.8 ± 15.9
TRPV1	9.3 ± 15.2	58.6 ± 9.0	-66.3 ± 20.1	-63.4 ± 49.4
TRPA1	-23.8 ± 12.6	-13.66 ± 113.03	58.3 ± 28.6	-32.99 ± 37.53
ASIC3	$\boldsymbol{0.8 \pm 7.2}$	7.5 ± 5.0	-82.77 ± 110.1	-76.33 ± 61.62
GFRa1	-2.8 ± 7.3	-81.8 ± 12.1**	-93.1 ± 26.8***	-97.6 ± 56.1***
GFRa2	30.3 ± 18.8	-44.8 ± 95.9	-55.9 ± 41.4	-69.2 ± 29.4
GFRa3	-7.6 ± 5.5	-60.5 ± 120.6	-18.5 ± 37.31	-37.8± 14.72
IL1r1	-17.9 ± 11.9	-90.1 ± 85.3*	-83.3 ± 28.5	-89.1± 7.9*

Table 3	Vehicle	PEGPH20	PEGPH20+AP	AP
1d	$5100.08 \pm 972.65 \text{ m}$	1034.07 ± 507.76 m*	297.27 ± 63.98 m**	$2118.52 \pm 622.81 \text{ m}$
2d	$4314.84 \pm 1028.88 \ m$	647.95 ± 237.69 m*	$97.19 \pm 92.70 \text{ m*}$	529.68 ± 225.32 m*
3d	5617.62 ± 1360.53 m	1091.83 ± 372.54 m	319.24 ± 113.41 m*	4541.73 ± 2236.27 m
4d	4566.33 ± 987.13 m	1457.09 ± 454.28 m*	64.62 ± 22.11 m*	419.32 ± 340.40 m*
5d	$4308.31 \pm 793.60 \text{ m}$	1624.41 ± 386.50 m*	216.20 ± 85.72 m** $^{#}$	1819.74 ± 1368.44 m*
6d	$4795.18 \pm 1037.20 \text{ m}$	2278.82 ± 616.13 m	151.05 ± 40.59 m* $^{\#}$	646.48 ± 496.81 m*
7d	5052.14 ± 1275.32 m	2393.98 ± 522.54 m	329.55 ± 108.71 m* #	2223.02 ± 1497.26 m